Standard
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. / Zimling, Zarah Glad; Sørensen, Jens Benn; Gerds, Thomas Alexander; Bech, Cecilia; Andersen, Claus Bøgelund; Santoni-Rugiu, Eric.
I:
Journal of Thoracic Oncology, Bind 7, Nr. 1, 2012, s. 249-56.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Zimling, ZG
, Sørensen, JB, Gerds, TA, Bech, C, Andersen, CB
& Santoni-Rugiu, E 2012, '
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival',
Journal of Thoracic Oncology, bind 7, nr. 1, s. 249-56.
https://doi.org/10.1097/JTO.0b013e318233d6a9APA
Zimling, Z. G.
, Sørensen, J. B., Gerds, T. A., Bech, C., Andersen, C. B.
, & Santoni-Rugiu, E. (2012).
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
Journal of Thoracic Oncology,
7(1), 249-56.
https://doi.org/10.1097/JTO.0b013e318233d6a9Vancouver
Zimling ZG
, Sørensen JB, Gerds TA, Bech C, Andersen CB
, Santoni-Rugiu E.
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
Journal of Thoracic Oncology. 2012;7(1):249-56.
https://doi.org/10.1097/JTO.0b013e318233d6a9Author
Zimling, Zarah Glad ; Sørensen, Jens Benn ; Gerds, Thomas Alexander ; Bech, Cecilia ; Andersen, Claus Bøgelund ; Santoni-Rugiu, Eric. / Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. I: Journal of Thoracic Oncology. 2012 ; Bind 7, Nr. 1. s. 249-56.
Bibtex
@article{6274a289b26b4dd68e639fd733b8e237,
title = "Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival",
abstract = "The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.",
author = "Zimling, {Zarah Glad} and S{\o}rensen, {Jens Benn} and Gerds, {Thomas Alexander} and Cecilia Bech and Andersen, {Claus B{\o}gelund} and Eric Santoni-Rugiu",
year = "2012",
doi = "10.1097/JTO.0b013e318233d6a9",
language = "English",
volume = "7",
pages = "249--56",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier",
number = "1",
}
RIS
TY - JOUR
T1 - Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival
AU - Zimling, Zarah Glad
AU - Sørensen, Jens Benn
AU - Gerds, Thomas Alexander
AU - Bech, Cecilia
AU - Andersen, Claus Bøgelund
AU - Santoni-Rugiu, Eric
PY - 2012
Y1 - 2012
N2 - The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.
AB - The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.
U2 - 10.1097/JTO.0b013e318233d6a9
DO - 10.1097/JTO.0b013e318233d6a9
M3 - Journal article
C2 - 22031231
VL - 7
SP - 249
EP - 256
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 1
ER -
